Definitive Contract 75N93023C00017

Award Date 6/1/23
Potential Completion Date 5/31/25
Potential Value $2M
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
East Case, MD 21202, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase II Action
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the U.S. Department of Health and Human Services, to Accelevir Diagnostics LLC, a woman-owned small business. The contract, valued at $299,975.00, is for the company to adapt its Intact Proviral DNA Assay (IPDA) to measure latent HIV-1 for individuals with the CRF-1_AE genetic subtype of the virus. This contract is part of NIAID's Small Business Innovation Research (SBIR)...
The Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) awarded a $13,500 firm fixed-price purchase order contract to Accelevir Diagnostics LLC, a woman-owned small business, for custom DNA assay analysis services. Accelevir Diagnostics is a research and development company that specializes in HIV diagnostics and measurement of the HIV latent reservoir. This contract was not set aside. Accelevir Diagnostics...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the U.S. Department of Health and Human Services, has awarded a $299,968 Small Business Innovation Research (SBIR) Phase I contract to Vitruvian Bio, LLC, a small disadvantaged and woman-owned business. The contract is for the development of an "Electrochemical Self-Monitoring Device for Rapid Nucleic Acid Based Testing of HIV-1". This specialized medical research and diagnostic technology...
The Department of Health and Human Services, National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases awarded a Small Business Innovation Research (SBIR) Phase I contract to Fluid Discovery, Inc., a for-profit small business, to develop "Multiplexed Droplet Digital Nucleic Acid Amplification Technologies for HIV Diagnosis." The $299,903 firm-fixed-price contract, which runs through July 31, 2024, supports research and development of innovative...
This is a $1,500,000.00 Small Business Innovation Research (SBIR) Phase II contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the Department of Health and Human Services, to Cure Systems LLC, a self-certified small disadvantaged business located in Newton, Massachusetts. The contract is for the research and development of "Vector-Based Delivery of HIV Broadly Neutralizing Antibodies," a specialized approach to developing advanced...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Darwin Biosciences, Inc., a minority-owned, woman-owned small business based in Broomfield, Colorado. The $299,408 firm-fixed-price contract is for the development of rapid diagnostic assays to aid in the self-monitoring of acute or rebound HIV-1 infection. The contract has an ultimate completion date of April 14, 2025. As an SBIR Phase I award,...
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $306,206.00 firm fixed-price Small Business Innovation Research (SBIR) Phase I contract to Intuitive Biosciences Inc., a small disadvantaged business, to develop "THE EV-HIV ASSAY, A POINT-OF-CARE LATERAL FLOW IMMUNOASSAY TO ACCURATELY IDENTIFY HIV INFECTION FROM BLOOD-BASED EXTRACELLULAR VESICLES." This contract is linked to a broader SBIR solicitation issued by the NIAID and Centers for Disease Control...
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services (HHS), to Southern Research Institute, a non-profit research organization. The $999,976 cost-plus-fixed-fee contract is for services to identify inhibitors of HIV-1 capsid dimerization as part of NIAID's In Vitro Testing Resource for HIV Therapeutics and Topical Microbicides program. The contract has no set-aside designation and is...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Firm Fixed Price Definitive Contract to Ai Biosciences, Inc., a minority-owned, self-certified small disadvantaged business, for the development of a low-cost, automated, and rapid home HIV viral load test. The award, which is part of the Small Business Innovation Research (SBIR) Program Phase I, has a potential value of $294,538.00 and a completion date of...
This federal contract award, valued at $299,659.00, was granted to Big Eye Diagnostics Inc., a small business manufacturer of goods, by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH). The contract is part of the Small Business Innovation Research (SBIR) program and is a Definitive Contract with a Firm Fixed Price pricing type. The contract is for the development of an "easy-to-use, low-cost triplex RDT for the...

The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $2M definitive contract to Accelevir Diagnostics LLC of East Case, MD. The contract is for ProViral Sequencing Driven Development of EnHanced IPDAV2 with Global HIV-1 Group M Coverage to Support Worldwide Cure and Clinical Trials. The prime contractor will perform research and development of enhanced diagnostics to support global HIV cure and clinical trials under this Small Business Innovation Research Program Phase II Action contract. The period of performance is from June 1, 2023 through May 31, 2025 under firm fixed pricing. The contract was set aside for total small businesses.

Generated 11/28/23, 12:18 PM